Head and Neck Cancer Clinical Trial
— ECHO-07Official title:
Induction Chemotherapy With Cetuximab, Docetaxel, Cisplatin, and Fluorouracil (ETPF) in Patient With Resectable Stage III-IV Squamous Cell Carcinoma of the Oropharynx
Verified date | August 2012 |
Source | GERCOR - Multidisciplinary Oncology Cooperative Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with cetuximab may kill more tumor cells. PURPOSE: This phase II clinical trial is studying how well cetuximab given together with combination chemotherapy works in treating patients with stage III or stage IV oropharynx cancer that can be removed by surgery.
Status | Completed |
Enrollment | 42 |
Est. completion date | July 2012 |
Est. primary completion date | July 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | DISEASE CHARACTERISTICS: - Histologically confirmed squamous cell carcinoma of the oropharynx - Stage III (T3 or T1-2, N1-2, M0) or nonmetastatic stage IV (T4 or T1-3, N3, M0) disease - Resectable disease - Measurable or evaluable disease - Tumor tissue available PATIENT CHARACTERISTICS: Inclusion criteria: - WHO performance status 0-1 - ANC = 1,500/mm3 - Platelet count = 100,000/mm3 - Hemoglobin = 9 g/dL - Creatinine < 1.5 times upper limit of normal (ULN) - Creatinine clearance = 60 mL/min - AST and ALT < 5 times ULN - Bilirubin < 1.5 times ULN - Not pregnant or nursing - Fertile patients must use effective contraception - Affiliated with social security (including CMU) Exclusion criteria: - Cardiovascular accident (myocardial infarction, cerebral vascular accident) within the past 6 months - Serious and/or uncontrolled cardiac or respiratory disease (pulmonary fibrosis, interstitial pneumopathy) - Other cancer within the past 5 years except for resected skin cancer, localized cutaneous or totally resected melanoma, or resected carcinoma in situ of the cervix - Auditory condition precluding the use of cisplatin - Contraindication due to psychological, social, or geographical reasons that may impede proper monitoring of treatment - Persons under guardianship or trusteeship, or prisoners of law PRIOR CONCURRENT THERAPY: - No prior treatment, including chemotherapy or radiotherapy - No concurrent phenytoin, live attenuated vaccines, or parenteral aminoglycosides |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Simone Veil | Montmorency | |
France | Hopital Bichat - Claude Bernard | Paris | |
France | Hopital Europeen Georges Pompidou | Paris | |
France | Hôpital Privé St Joseph | Paris | |
France | Hopital Tenon | Paris | |
France | centre Hospitalier Lyon Sud | Pierre Benite | |
France | Centre René Huguenin | Saint Cloud | |
France | Hopital Foch | Suresnes |
Lead Sponsor | Collaborator |
---|---|
GERCOR - Multidisciplinary Oncology Cooperative Group |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Biomarkers Analysis - HPV Genotyping | correlative studies investigating HPV status in tumor and blood samples obtained prior to and after induction therapy were done for exploratory purposes as planned in the protocol | ||
Primary | Clinical and Radiological Complete Clinical Response (crCR) Rate at 3 Months | The evaluation of tumor response rate was assessed by computed tomography scan of the neck and chest at Baseline, then at 3 months from inclusion using RECIST1.0 criteria and clinical examination | at 3 months after ETPF combination | |
Secondary | Complete Clinical Response (cCR) | Clinical complete response (cCR) is defined by: Disappearance of all clinical evidence of visible tumor, Disappearance of all palpable residual infiltration, Disappearance of all evidence of residual visible tumor on CT scan in pharynx and parapharyngeal space, Complete symmetric remobilization of the tongue and amygdala. Disappearance of pre-existing trismus. Negative control biopsy. The evaluation of tumor response rate was assessed by computed tomography scan of the neck and chest at Baseline, then at 3 months from inclusion using RECIST1.0 criteria and clinical examination |
at 3 months | |
Secondary | The 2-year Estimated Overall Survival (OS) Rate | 2-year OS measured survival at 2 years from randomization. | 2 years | |
Secondary | Pathologic Response | On primary tumor resected : measure of persistence or not of tumoral lesion, histological type, size and quality of the excision piece A pathological complete response is defined as no viable tumour cells detected on histological examination post surgery. |
after surgery of the primary tumor | |
Secondary | The 2-year Estimated Progression-free Survival (PFS) | 2-year PFS measured survival at 2 years from randomization. | 2 years | |
Secondary | Complete Radiological Response (rCR) | Radiological response is defined according to RECIST 1.0 criteria: Complete response (CR): disappearance of all target lesions Partial response (PR): at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter, Progressive disease (PD): at least a 20% increase in the sum of the longest diameter of target the appearance of one or more new lesions, Stable disease (SD): neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started |
At 3 months after the end of 3 cycles of the ETPF combination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |